After validating that IFNγR1−/− B16Nectin1 cells were truly insensitive to IFNγ-mediated effects, we challenged wild-type mice with either control or IFNγR1−/− tumor cells, established palpable tumors, and began treatment with dual checkpoint blockade or IL-12 virotherapy. The gene discussed is IFNGR1; the disease is neoplasm.